SCHEMBL6834673

SCHEMBL6834673

Fc1ccc2c(c1)-c1[nH]c(-c3ccncc3)nc1CCC2

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 6/20 0.67
MAPK13 O15264 12/20 0.46
MAPK12 P53778 12/20 0.46
MAPK11 Q15759 12/20 0.46
MAPK14 Q16539 12/20 0.46
GCGR P47871 11/20 0.46
PRKD3 O94806 3/20 0.46
MAP4K4 O95819 3/20 0.46
FRK P42685 3/20 0.46
MAPK9 P45984 3/20 0.46
CSNK1A1 P48729 3/20 0.46
CSNK1D P48730 3/20 0.46
GSK3B P49841 3/20 0.46
CLK4 Q9HAZ1 3/20 0.46
PTK6 Q13882 2/20 0.46
PRKD2 Q9BZL6 2/20 0.46
RAF1 P04049 2/20 0.43
ALOX5 P09917 5/20 0.42
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6836929 0.86 NPY5R (0.69) NPY5RKDM4EALDH1A1HPGDMAPT
SCHEMBL6835195 0.85 NPY5R (0.48) NPY5RMAPK13MAPK12MAPK11MAPK14
SCHEMBL6835539 0.85 NPY5R (0.67) NPY5RMAPK13MAPK12MAPK11MAPK14
SCHEMBL6835180 0.82 NPY5R (0.69) NPY5RMAPK13MAPK12MAPK11MAPK14
SCHEMBL6836970 0.82 NPY5R (0.64) NPY5RMAPK13MAPK12MAPK11MAPK14
SCHEMBL6834518 0.81 NPY5R (0.68) NPY5RKDM4EHPGDLMNAMAPT
SCHEMBL6835211 0.73 NPY5R (0.66) NPY5RMAPK13MAPK12MAPK11MAPK14
SCHEMBL6835188 0.72 NPY5R (0.61) NPY5RMAPK13MAPK12MAPK11MAPK14
SCHEMBL6835859 0.71 NPY5R (0.69) NPY5RMAPK14KDM4EALDH1A1CYP1A2
SCHEMBL6567519 0.71 NPY5R (0.49) NPY5RMAPK14KDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040198791-A1 Fused imidazole derivative FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198791-A1 Fused imidazole derivative H1-0, H1-5, H1-3 NPY5R 983/4885MAPK13 4148/4885MAPK12 4196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.